Equities

Trimax Corp

  • Add to watchlist
  • Add to portfolio
  • Add an alert
TMXN:PKC

Trimax Corp

Actions
  • Price (USD)0.0022
  • Today's Change0.00 / 0.00%
  • Shares traded19.00k
  • 1 Year change+101.83%
  • Beta0.0092
Data delayed at least 15 minutes, as of Feb 09 2026 14:33 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Trimax Corporation is a holding company for healthy skincare, fitness, anti-aging, therapy products and a portfolio of beauty, cosmetic and personal care focused on serving people of color. The Company also has an agreement to acquire a San Diego-based infrared, health, fitness, anti-aging and therapy product operator in an all-stock transaction. Its products and licenses being evaluated in addition to the Trimax platform include a portable gym in a box, training videos, heat shock protein stimulation, and books on elements for the quickest and effective workouts.

  • Revenue in USD (TTM)--
  • Net income in USD--
  • Incorporated1999
  • Employees--
  • Location
    Trimax Corp1007 N Federal Hwy, #275FORT LAUDERDALE 33304United StatesUSA
  • Phone+1 (302) 261-3660
  • Fax+1 (619) 348-5066
  • Websitehttps://www.saavynaturals.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Petros Pharmaceuticals Inc725.40k-62.70m322.03k18.00--0.0954--0.4439-36.75-37.380.04160.07970.0541----40,300.00-100.17-30.30-233.69-61.2663.5068.57-1,852.35-210.20----0.00---12.20-19.98-93.98---19.23--
Trimax Corp-100.00bn-100.00bn587.06k-----------------0.0003------------------------0.0329--2.36--3.40--105.56------
LogicMark Inc10.61m-9.87m616.12k31.00--0.0298--0.0581-1,486.41-1,486.4127.8025.560.55233.88170.03342,234.80-49.83-37.74-56.09-43.6465.8364.82-90.21-84.665.18--0.00---0.2784-10.3941.04--1.45--
Nano Mobile Healthcare Inc0.00-5.46m654.75k3.00---------0.2255-0.22550.00-0.01290.00----0.00-10,475.82-----------------0.3173----------------
Electromedical Technologies Inc922.02k-1.68m746.46k6.00------0.8096-0.0035-0.00350.001-0.00551.302.95112.10153,670.00-236.02-340.23----75.0875.94-182.03-406.260.0645-1.02----17.3014.8426.05------
Medical Care Technologies Inc.0.00-1.07m821.00k0.00---------553,570.10-553,570.100.00-389.230.00-------154.94-----------------1.46---------40.06------
Zynex Inc108.20m-73.96m942.05k1.00k------0.0087-2.43-2.433.49-1.341.262.207.64108,202.00-86.3110.48-203.5512.4271.9079.57-68.357.510.3174-12.223.19--4.3633.44-69.24-20.6129.29--
CYIOS Corp1.49m-59.20k984.30k15.00--0.3734--0.6592-0.0016-0.00160.04110.00863.51--9.5199,542.66-13.93-21.69-17.32-60.1543.6742.72-3.96-4.54----0.0867--4.142.47130.18------
Venus Concept Inc58.88m-54.61m1.10m292.00--0.4104--0.0186-46.93-46.9348.241.440.87941.213.13201,630.10-81.66-34.89-199.53-47.8164.3667.86-92.86-54.810.5934-6.680.9056---15.09-10.10-26.16---35.75--
Data as of Feb 09 2026. Currency figures normalised to Trimax Corp's reporting currency: US Dollar USD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.